{"organizations": [], "uuid": "3df987b271773577ab2960b263164a1dbce223c6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180402.html", "section_title": "Archive News &amp; Video for Monday, 02 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/alkermes-fda/fda-rejects-application-to-review-alkermes-depression-treatment-idUSL4N1RF3LW", "country": "US", "domain_rank": 408, "title": "FDA rejects application to review Alkermes' depression treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.212, "site_type": "news", "published": "2018-04-02T19:15:00.000+03:00", "replies_count": 0, "uuid": "3df987b271773577ab2960b263164a1dbce223c6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/alkermes-fda/fda-rejects-application-to-review-alkermes-depression-treatment-idUSL4N1RF3LW", "ord_in_thread": 0, "title": "FDA rejects application to review Alkermes' depression treatment", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "shailesh kuber", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "alkermes", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "alkermes plc", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 2 (Reuters) - Alkermes Plc said on Monday the U.S. Food and Drug Administration rejected the application seeking approval for its experimental depression drug, citing insufficient evidence of effectiveness.\nThe company said it strongly disagreed with the FDA and planned to appeal the regulator’s decision after the regulator sent a “Refusal to File” letter to the company.\nThe drug, ALKS 5461, is being tested as adjunctive treatment of major depressive disorder in patients with an inadequate response to standard antidepressant therapies. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-02T19:15:00.000+03:00", "crawled": "2018-04-03T16:18:09.000+03:00", "highlightTitle": ""}